CVS Health Corporation $CVS Shares Sold by Y.D. More Investments Ltd

Y.D. More Investments Ltd decreased its holdings in CVS Health Corporation (NYSE:CVS) by 59.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,040 shares of the pharmacy operator’s stock after selling 1,510 shares during the quarter. Y.D. More Investments Ltd’s holdings in CVS Health were worth $72,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of CVS. Vanguard Group Inc. boosted its stake in shares of CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after buying an additional 969,027 shares during the period. Dodge & Cox lifted its position in CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after acquiring an additional 3,353,223 shares during the period. Geode Capital Management LLC increased its holdings in shares of CVS Health by 2.4% in the second quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock valued at $1,966,083,000 after purchasing an additional 675,824 shares during the period. Invesco Ltd. increased its holdings in shares of CVS Health by 13.2% in the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of CVS Health by 14.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock worth $1,037,205,000 after purchasing an additional 1,942,886 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Up 0.6%

Shares of CVS stock opened at $78.24 on Tuesday. The stock has a market cap of $99.32 billion, a P/E ratio of 205.89, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a quick ratio of 0.62, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $85.15. The business has a fifty day simple moving average of $77.86 and a 200-day simple moving average of $70.02.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. During the same period in the previous year, the firm earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Thursday, October 23rd. CVS Health’s payout ratio is currently 700.00%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CVS. Mizuho increased their price target on shares of CVS Health from $76.00 to $88.00 and gave the stock an “outperform” rating in a report on Thursday, October 9th. The Goldman Sachs Group began coverage on CVS Health in a research note on Tuesday, October 14th. They issued a “buy” rating and a $91.00 price target on the stock. Truist Financial reiterated a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of CVS Health in a research report on Thursday, October 30th. Zacks Research cut shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Finally, Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Monday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.41.

Insider Transactions at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.22% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.